Navigation Links
Aderans Research Treats One-Hundredth Subject in Clinical Study
Date:2/28/2010

Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

Atlanta, GA (PRWEB) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

“The breadth of this phase of our trial is tremendous,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on pattern hair loss.”

Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months.

The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth.

“This is leading edge research in our industry,” said Vern Liebmann, Vice President, Operations. “We’ve been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we’re collectively very excited to see the results beginning later this year.”

Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI’s cellular regeneration techniques.

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html

Additional information on ARI can be found at www.aderansresearch.com.

Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/

###

Read the full story at http://www.prweb.com/releases/hair/regeneration/prweb3661844.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Aderans Research BIO International Press Release
2. Aderans Research Launches Second Phase of Hair Loss Study
3. Veterans Affairs Researchers Induce a New Transmissible Prion Disease
4. Hypnosis can help control pain among women with metastatic breast cancer, UB Researcher finds
5. New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers
6. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
7. Multiple sclerosis, Italian researchers discover a possible onset mechanism for the disease
8. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Commitment to Pulmonary Fibrosis Research
9. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
10. New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery
11. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aderans Research Treats One-Hundredth Subject in Clinical Study
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
Breaking Medicine Technology: